1 / 1

Role of Hematopoietic Growth Factors in the Prevention of Neutropenic Complications for Breast Cancer Patients Treated with Docetaxel, Doxorubicin, and Cyclophosphamide (TAC): Results of a Randomized Double-Blind Phase III Trial BCIRG 004.

wei
Télécharger la présentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Role of Hematopoietic Growth Factors in the Prevention of Neutropenic Complications for Breast Cancer Patients Treated with Docetaxel, Doxorubicin, and Cyclophosphamide (TAC): Results of a Randomized Double-Blind Phase III Trial BCIRG 004 John R. Mackey1, Jacques Cantin2, Jose Chang3, Raymond Guervin4, Ravi Patel5, Katherine Tkaczuk6, Pavel Vodvarka7, Michael Needle8, Thomas Peppard8, Jeffery Nieves8, Jean-Marc Nabholtz9, on behalf of the Breast Cancer International Research Group 1Cross Cancer Institute, Edmonton, AB, Canada; 2CHUM Campus Hotel Dieu, Montreal, QC, Canada; 3Oshawa general Hospital/Lakeridge Health Oshawa, Oshawa, ON, Canada; 4CHUM Pavillon Saint-Luc, Montreal, QC, Canada; 5Comprehensive Blood and Cancer Center, Bakersfield, CA; 6Greenebaum Cancer Centre, Baltimore, MD; 7FNsP Ostrava, Ostrava - Poruba, Czech Republic; 8Pharmacia, Skokie, IL; 9Univ. California at Los Angeles, CA.

More Related